dc.contributor.author | Andersen, Thomas | |
dc.contributor.author | Ueland, Thor | |
dc.contributor.author | Aukrust, Pål | |
dc.contributor.author | Nilsen, Dennis W.T. | |
dc.contributor.author | Grundt, Magnea Heidi Jonsdottir | |
dc.contributor.author | Staines, Harry | |
dc.contributor.author | Kontny, Frederic | |
dc.date.accessioned | 2022-08-05T08:52:01Z | |
dc.date.available | 2022-08-05T08:52:01Z | |
dc.date.created | 2022-07-18T12:40:59Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 2297-055X | |
dc.identifier.uri | https://hdl.handle.net/11250/3010280 | |
dc.description.abstract | Background: Markers of bone and extracellular matrix (ECM) remodeling may be associated with adverse outcomes in atherosclerotic cardiovascular disease. Podocan is a newly discovered ECM glycoprotein, previously not studied in a chest pain population. We wanted to study the association between Podocan levels on admission and the risk of adverse outcomes in a chest pain population with suspected acute coronary syndromes. Methods: A total of 815 patients from the Risk markers in Acute Coronary Syndrome (RACS) trial with suspected coronary chest pain were followed for 7 years. Blood samples were taken immediately after inclusion and stored in the biobank. Associations between Podocan and endpoints were assessed with Cox proportional hazards analyses. Results: The median admission level of Podocan was 0.674 ng/ml (0.566–0.908 ng/ml). No significant association was found between Podocan quartile levels and all-cause death, neither at 1 year nor 2- or 7-years follow-up (p > 0.05 for all). Furthermore, no significant association could be shown between Podocan and cardiac death, myocardial infarction (MI), stroke, or the composites of all-cause death/MI/stroke or cardiac death/MI/stroke (p > 0.05 for all). Similarly, in a subgroup of patients with Troponin T-positive (n = 432) there was no significant association between Podocan and any of the outcome measures (p > 0.05 for all endpoints and points in time). Conclusion: Podocan, a novel ECM biomarker, is not associated with all-cause mortality or other major cardiovascular adverse events in patients admitted with acute chest pain suspected to be of coronary origin. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Frontiers | en_US |
dc.relation.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163367/pdf/fcvm-09-867944.pdf | |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Podocan and Adverse Clinical Outcome in Patients Admitted With Suspected Acute Coronary Syndromes | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 The Author(s) | en_US |
dc.source.articlenumber | 867944 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.3389/fcvm.2022.867944 | |
dc.identifier.cristin | 2038635 | |
dc.source.journal | Frontiers in Cardiovascular Medicine | en_US |
dc.relation.project | Regionalt helseforetak: N/A | en_US |
dc.identifier.citation | Frontiers in Cardiovascular Medicine. 2022, 9, 867944. | en_US |
dc.source.volume | 9 | en_US |